Share this article

PerkinElmer has announced the launch of new G Protein-Coupled Receptor (GPCR) TR-FRET Binding Assay and Beta-Arrestin kits to help advance therapeutic discovery.

The assays extend PerkinElmer’s GPCR analysis portfolio that includes new assays, plate readers, automation technologies and software solutions combined with siRNA, shRNA, CRISPR, and cDNA/ORF libraries.

They help in easy and accurate characterisation of receptors, screen compounds and streamline workflows.

Furthermore, the assays enable researchers in using the preferred cell models of their choice.

They include the HTRF GTP Gi binding kit, the Time-resolved fluorescence energy transfer- (TR-FRET) based assay for GTP binding, the B-arr2 recruitment kit and HTRF total kits for B-Arrestin 1, B-Arrestin 2 and AP2.

These assays can help scientists in better understanding the role of GPCRs in diseases by studying the interaction, expression and potential modulation of intracellular proteins involved in GPCR signalling mechanisms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

PerkinElmer noted that when the new assay kits are used as part of its comprehensive range of GPCR solutions, users can completely characterise the GPCRs being studied.

They range from ligand binding with the Tag-Lite platform and second messenger with the cAMP and IP-One kits, to downstream GPCR signalling with several assays that are available.

The company’s portfolio also includes siRNA, shRNA, CRISPR guide RNA, and cDNA/ORF libraries, such as ON-TARGETplus, SMARTvector and Edit-R and screening services, with the recent acquisition of Horizon Discovery.

With this portfolio, researchers will be able to explore the impact of gene modulation and editing on GPCR disease drivers.

PerkinElmer vice-president and Life Sciences general manager Alan Fletcher said: “With GPCR-targeting drugs accounting for more than 30% of all FDA approved therapeutics and 20% of all drugs being studied, this area of research and development has been incredibly fruitful and holds immense potential for the future.

“By adding these new assays to our already robust GPCR capabilities, we are giving researchers an end-to-end solution for continuing to unlock the role GPCRs play in disease so new and better therapeutics can be uncovered.”

Last October, PerkinElmer secured CE Mark approval in the EU for its PKamp Respiratory SARS-CoV-2 RT-PCR panel.

The panel helps in detecting SARS-CoV-2 and other influenza viruses in a single test.